What Envision Pharma Group does

Envision Pharma Group is a global, technology-enabled solutions partner for the life sciences industry, founded in 2001 and majority-owned by private equity firm GHO Capital since November 2021. The company serves 400+ pharmaceutical, biotechnology, and medical technology organizations — including all top 20 pharma companies — from 14 offices across the UK, continental Europe, North America, and Asia-Pacific, with a workforce of 1,001-5,000 employees.

The company's core offering is a connected technology ecosystem anchored by EnvisionOne (the integrated operating framework for medical affairs with Datavision-powered publications at its center) and iEnvision (a SaaS platform for managing publication planning, investigator-sponsored research, medical education, and corporate funding grants). Adjacent platforms include EnvisionOne Insights & Analytics for AI-driven benchmarking, Envision AI Labs for proprietary AI innovation, and the Riparian Cloud Platform for revenue management and market access. These platforms are delivered alongside strategic service solutions — including medical communications (via Envision 90TEN, Spark, Ignite, and Catalyst agencies), strategic consulting, commercialization services (via Two Labs), and revenue management (via Riparian) — and are extended through acquired AI capabilities from OKRA.ai (2023) and document collaboration technology from doDOC Corp (2025).

Envision generates revenue through a mix of quote-based, enterprise subscription pricing for its SaaS platforms, managed services engagements for outsourced functions, and high-touch professional services for strategic consulting and medical communications. Its go-to-market is enterprise-led, leveraging direct field sales and consultative partnerships with global pharma. AI is positioned as a core differentiator — embedded across the platform for generative content, knowledge retrieval, predictive analytics, and process automation — and the company holds ISO/IEC 27001:2022 certification and an EcoVadis Gold Medal sustainability rating.

Name

Envision Pharma Group

Legal name

Envision Pharma Group Limited

Website

https://www.envisionpharmagroup.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Envision Pharma Group is a global, PE-backed technology-enabled services partner for life sciences, serving 400+ pharma, biotech, and medtech clients — including all top 20 pharma — through its EnvisionOne connected platform, medical communications agencies, and acquired AI and revenue management capabilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Services

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare/Pharma Creative Agencies (MPAAAAAJ)

Keywords

• Medical affairs services
• Scientific communications solutions
• Pharmaceutical consulting
• Medical publications planning
• Life sciences technology

Headquarters

HQ city

Southport

HQ country

United States

HQ region

North America

Offices14 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Strategic Consulting Services: Evidence-led insight, strategy, and advisory support across the product lifecycle covering clinical and medical strategy, brand and commercial strategy, stakeholder strategy, competitive intelligence, risk evaluation, and operational excellence.
2. Medical Communications: Connected medical affairs and communications solutions including scientific and medical strategy, publications strategy and delivery, omnichannel engagement, patient advocacy, and value and evidence services.
3. Commercialization Services: Launch strategy and execution, trade and channel strategy, patient support services, and compliance services delivered through Two Labs subsidiary.
4. Revenue Management and Market Access: Pricing, access, and value optimization through Riparian business unit, including technology platforms, managed services, consulting, and market access capabilities.
5. Technology Solutions: AI-enabled technology platforms including EnvisionOne, iEnvision, and Envision AI Labs, providing SaaS solutions for medical affairs, publications planning, and AI-driven insights.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Envision Pharma Group provides integrated strategic consulting, medical communications, commercialization, revenue management, and market access services for life sciences organizations, supported by proprietary AI-enabled technology platforms (EnvisionOne, iEnvision, Envision AI Labs, and Riparian Cloud Platform). The company operates a connected operating model that combines deep scientific and compliance expertise with technology-enabled delivery across the product lifecycle, from evidence generation through commercialization.

Product overview

Envision Pharma Group offers a unified, integrated portfolio of technology platforms and specialized services for life sciences. The core ecosystem centers on EnvisionOne as the connected operating framework, with iEnvision serving as the SaaS platform for medical affairs project management. EnvisionOne Insights & Analytics provides benchmarking and journal profiling for publications strategy, while Envision AI Labs drives proprietary AI innovation. Supporting the platforms are Riparian (revenue management and market access via the Riparian Cloud Platform), Two Labs (commercialization services), and Envision Medical Communications delivered through four specialist agencies (Envision 90TEN, Envision Spark, Envision Ignite, and Envision Catalyst). The company has expanded its AI capabilities through strategic acquisitions of OKRA.ai (2023) and doDOC Corp (2025), integrating advanced AI solutions and document collaboration into its connected technology ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

• EnvisionOne Central operating framework for Envision's connected model for medical affairs, with publications powered by Datavision at the center. Connects strategy, data, workflows, insights, AI, and human expertise in one integrated platform, enabling pharmaceutical teams to transform scientific insight into measurable value.
• iEnvision SaaS platform designed for the complex needs of global medical affairs, supporting best practices in publication planning, investigator-sponsored research, medical education, and corporate funding grants with structure, transparency, and compliance for every stage of medical project lifecycle.
• EnvisionOne Insights & Analytics Advanced benchmarking and journal-profiling solution for medical publications that delivers AI-driven insights, industry analytics, and strategy optimization. Compares data against anonymized industry benchmarks to uncover opportunities and centralize scientific communications.
• Envision AI Labs Dedicated AI innovation hub focused on combining human expertise with advanced artificial intelligence. Powers transformation across AI-enabled teams, AI-accelerated delivery, and AI-infused platforms built with machine learning at the core, supporting commercialization, real-world evidence, data analytics, medical affairs, and pricing.
• Riparian Cloud Platform Full end-to-end revenue management solution for master data management, chargeback processing, gross-to-net forecasting, rebate adjudication, and government pricing. Ranked Top 10 Enterprise Solution Provider by PharmaTech Outlook magazine.
• Two Labs Envision subsidiary specializing in helping emerging and mid-sized biopharma companies bring therapies to market with speed, precision, and confidence. Offers end-to-end launch strategy, trade and channel strategy, patient support services, and compliance solutions.
• Envision Medical Communications Medical communications division partnering with medical affairs teams on scientific publications, omnichannel engagement, and strategic storytelling, delivered through four specialist agencies: Envision 90TEN, Envision Spark, Envision Ignite, and Envision Catalyst.
• Strategic Consulting Services Evidence-led insight, strategy, and advisory support across the product lifecycle covering clinical and medical strategy, brand and commercial strategy, stakeholder strategy, competitive intelligence, risk evaluation, and operational excellence.
• Revenue Management and Market Access Services Pricing, access, and value optimization for pharmaceutical and biotech companies through the Riparian business unit, including technology platforms, managed services, consulting, and market access capabilities.
• OKRA.ai AI solutions provider specializing in advanced AI for commercialization, real-world evidence, data analytics, medical affairs, and pricing across the life sciences sector.
• doDOC Document collaboration firm for pharma and life sciences industries, operating as a business unit integrating with Envision's platform to provide efficiency gains in document processes.

Quantifiable outcome

• AI-driven platforms improving insight generation time by up to 70%
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• doDOC CorpcoreTechnology or Integration · 12 November 2025Acquired doDOC Corp, a document collaboration firm for pharma and life sciences industries. doDOC operates as a business unit integrating with Envision's platform, providing efficiency gains in document processes.
• OKRA.aicoreTechnology or Integration · 7 February 2023Acquired OKRA.ai, a UK and Netherlands-based AI solutions provider for pharmaceutical and life sciences. The integration enhances Envision's capabilities across the product lifecycle and improves patient outcomes through advanced AI for commercialization, real-world evidence, data analytics, medical affairs, and pricing.
• RipariancoreStrategic or Co-development Partner · 17 July 2021Two Labs acquired Riparian, a business unit focused on pricing, access, and value optimization for pharmaceutical and biotech companies. Riparian provides revenue management and market access solutions powered by the Riparian Cloud Platform.
• AI Technology Partners (Semantic Search, Synthetic KOLs, Automated SCP)supportingTechnology or IntegrationStrategic partnerships with leading technology providers delivering advanced capabilities including semantic search, synthetic KOLs for scenario planning, and AI-driven automated scientific communication planning. These integrate best-in-class innovations into Envision's platforms.
• Two LabscoreStrategic or Co-development PartnerTwo Labs, an Envision Pharma Group company, specializes in helping emerging and mid-sized biopharma companies bring therapies to market. The company was acquired in 2021 and provides end-to-end launch strategy, trade management, patient support services, and compliance solutions.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Fishawack Health: Medical communications and publications agency serving global pharma and biotech, with strong overlap to Envision's medical affairs/scientific communications core. Comparable in scale, therapeutic-area depth, and reliance on medical affairs outsourcing spend.
• Cello Health (now part of Cello Group): Healthcare-focused strategic consulting and communications firm serving pharma clients, including medical affairs, scientific publications, and market access. Directly comparable to Envision's strategic services and medical communications offerings.
• Springer Healthcare (Springer Nature): Medical communications and publications services business serving pharma with similar scientific content and publication planning capabilities — comparable to Envision Medical Communications.
• Precision Medicine Group: Specialized life sciences services firm providing medical communications, market access, and commercialization solutions to emerging and established biopharma. Closely comparable in service mix and biotech-segment focus to Envision.
• Indegene: Healthcare commercialization and consulting firm providing medical affairs, market access, and digital/AI solutions to pharma. Comparable in client base, AI-driven service approach, and biotech-segment focus.

Broad incumbents

• ICON plc: Global CRO with acquired strategic consulting and commercialization capabilities. Larger and more clinically focused, but overlapping customers and adjacent services to Envision's strategic and commercialization offerings.
• Syneos Health: Large contract research and commercialization organization offering medical affairs and consulting services. Broader portfolio but comparable focus on pharma strategic services and life sciences communications.
• Real Chemistry (formerly W2O Group): Large healthcare marketing, communications, and consulting firm with overlapping scientific communications and AI-driven analytics capabilities. Broader focus on healthcare (not just pharma), but comparable communications-led model.
• IQVIA: Global CRO and healthcare data analytics giant with overlapping capabilities in medical affairs, real-world evidence, and commercial strategy. Much larger and broader, but competes for the same pharma customer wallet.

Emerging players

• ConcertAI: AI-focused life sciences analytics firm specializing in real-world evidence and commercial solutions for pharma/biotech — the source of Envision's new EMC President Nick Jones. Comparable in AI-driven pharma analytics, though narrower in service scope than Envision.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/envisionpharma
• LinkedInlinkedin.com/company/envision-pharma-group

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envision Pharma Group